SARS-CoV-2 and Acetylsalicylic Acid (SARA)

PHASE3CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

September 14, 2022

Primary Completion Date

May 23, 2024

Study Completion Date

May 23, 2024

Conditions
SARS-CoV2 InfectionCovid19
Interventions
DRUG

Low-dose acetylsalicylic acid

In case of being positive for SARS-CoV-2 PCR or antigen test, she will be randomised 1:1 to receive daily LDASA (125 mg) or placebo, up to 36 weeks of pregnancy.

DRUG

Placebo

Placebo

Trial Locations (4)

257

Universidade Eduardo Mondlane, Maputo

28850

Hospital Universitario de Torrejón, Torrejón de Ardoz

08003

Hospital del Mar, Barcelona

08950

Hospital Sant Joan de Déu, Barcelona

All Listed Sponsors
collaborator

Hospital Universitario de Torrejón

UNKNOWN

collaborator

Hospital Universitario Infanta Leonor

OTHER

collaborator

Hospital Sant Joan de Deu

OTHER

collaborator

Hospital del Mar

OTHER

collaborator

Eduardo Mondlane University

OTHER

collaborator

Hospital Central de Maputo

UNKNOWN

collaborator

Hospital Geral de Mavalane

UNKNOWN

collaborator

Hospital Geral José Macamo

UNKNOWN

lead

Barcelona Institute for Global Health

OTHER